Hypercholesterolemia Clinical Pipeline | 25+ Companies Leading the Next Breakthroughs

The Hypercholesterolemia market is evolving with cutting-edge research and new therapeutic advancements.

DelveInsight's 'Hypercholesterolemia Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Hypercholesterolemia therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Hypercholesterolemia pipeline domain.

For Hypercholesterolemia emerging drugs, the Hypercholesterolemia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Hypercholesterolemia Pipeline Report
• DelveInsight's Hypercholesterolemia Pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline drugs for Hypercholesterolemia treatment.
• The leading Hypercholesterolemia companies include Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics, and others are evaluating their lead assets to improve the Hypercholesterolemia treatment landscape.
• Key Hypercholesterolemia pipeline therapies in various stages of development include Lerodalcibep, MK-0616,SHR-1209, ARO-ANG 3, VXX-401, and others.
• In January 2025, IB Therapeutics Inc. (LIB) announced the publication of the Phase 3 LIBerate-HoFH study of Lerodalcibep, a novel third-generation PCSK9 inhibitor, in a globally diverse homozygous familial hypercholesterolemia (HoFH) population.
• In December 2021, the US FDA approved LEQVIO (inclisiran) injection as a treatment to be used along with diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH). LEQVIO works to reduce circulating levels of LDL-C, commonly known as "bad cholesterol."

Request a sample and discover the recent breakthroughs happening in the Hypercholesterolemia pipeline landscape @ https://www.delveinsight.com/report-store/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hypercholesterolemia Overview
Hypercholesterolemia, a form of hyperlipidemia, occurs when LDL cholesterol levels exceed healthy thresholds-rising above 190 mg/dL, or above 160 mg/dL with one major risk factor, or above 130 mg/dL with two cardiovascular risk factors. While some cases are inherited, the condition is often linked to lifestyle choices, making it largely preventable and manageable. A diet rich in fiber, fruits, vegetables, and healthy fats, combined with regular exercise, can help lower cholesterol levels. When necessary, cholesterol-lowering medications such as statins can further reduce LDL levels and significantly decrease the risk of cardiovascular disease.

Excess cholesterol in the bloodstream leads to plaque buildup inside the arteries, a process known as atherosclerosis. Over time, these fatty deposits narrow the blood vessels, restricting circulation and increasing the likelihood of heart attacks and strokes. Smaller plaques can rupture, forming dangerous blood clots that can suddenly block blood flow to vital organs. Though hypercholesterolemia itself has no symptoms, prolonged high cholesterol can contribute to serious complications. Restricted blood supply to the brain may cause transient ischemic attacks, resulting in dizziness, vision loss, difficulty speaking, or weakness on one side of the body.

Managing cholesterol effectively requires a proactive approach to heart health. Maintaining an optimal weight, avoiding smoking, and engaging in at least 150 minutes of physical activity per week all contribute to better cardiovascular outcomes. Plant stanols, at a dose of 2 grams per day, have been shown to help lower LDL cholesterol levels. When lifestyle changes are not enough, statins remain the most effective medical treatment, lowering LDL cholesterol by 22% to 50% and significantly reducing the risk of heart disease. Taking charge of cholesterol levels today can help prevent life-threatening complications and promote long-term heart health.

Find out more about Hypercholesterolemia medication @ https://www.delveinsight.com/report-store/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hypercholesterolemia Treatment Analysis: Drug Profile
SHR-1209: Jiangsu HengRui Medicine Co., Ltd.
Recaticimab (SHR-1209) is a cutting-edge monoclonal antibody (mAb) designed for long-acting inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). As an immunoglobulin G1 (IgG1) antibody, it offers a unique mechanism for modulating PCSK9 activity, contributing to the growing arsenal of therapies for hyperlipidemia and cardiovascular disease. This innovative approach positions SHR-1209 as a promising therapeutic option for cholesterol management. Currently, the drug is in the Preregistration stage for the treatment of hypercholesterolemia.

MK-0616: Merck Sharp & Dohme LLC
MK-0616 is an investigational oral PCSK9 inhibitor designed to effectively lower low-density lipoprotein (LDL) cholesterol. Developed by Merck in collaboration with UCB Pharmaceuticals, MK-0616 is a macrocyclic peptide that binds to PCSK9, preventing its interaction with LDL receptors. In Phase IIb clinical trials, MK-0616 demonstrated a favorable safety profile, with no significant trends in adverse events or treatment-related discontinuations over 16 weeks. No investigator-reported serious adverse events linked to the drug were observed. Currently, MK-0616 is in Phase III development for the treatment of hypercholesterolemia.

ARO-ANG3: Arrowhead Pharmaceuticals
ARO-ANG3 is an investigational RNA interference (RNAi) therapy aimed at reducing the expression of angiopoietin-like protein 3 (ANGPTL3), a key regulator of lipid and lipoprotein metabolism. By inhibiting ANGPTL3, this therapy may enhance the clearance of LDL cholesterol, HDL cholesterol, and triglycerides, potentially improving overall lipid balance. Given its role in regulating lipoprotein metabolism, ARO-ANG3 represents a novel approach to cholesterol management. Currently, it is in Phase II clinical trials for the treatment of hypercholesterolemia.

Key Hypercholesterolemia Therapies and Companies
• Lerodalcibep: LIB Therapeutics
• MK-0616: Merck Sharp & Dohme /UCB Pharmaceuticals
• SHR-1209: Jiangsu HengRui Medicine Co., Ltd.
• ARO-ANG 3: Arrowhead Pharmaceuticals
• VXX-401: Vaxxinity, Inc.

Learn more about the novel and emerging Hypercholesterolemia pipeline therapies @ https://www.delveinsight.com/report-store/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hypercholesterolemia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Hypercholesterolemia Pipeline Report
• Coverage: Global
• Key Hypercholesterolemia Companies: Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics, and others.
• Key Hypercholesterolemia Pipeline Therapies: Lerodalcibep, MK-0616,SHR-1209, ARO-ANG 3, VXX-401, and others.

Dive deep into rich insights for drugs used for Hypercholesterolemia treatment; visit @ https://www.delveinsight.com/report-store/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Hypercholesterolemia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hypercholesterolemia Pipeline Therapeutics
6. Hypercholesterolemia Pipeline: Late-Stage Products (Phase III)
7. Hypercholesterolemia Pipeline: Late-Stage Products (Phase III)
8. Hypercholesterolemia Pipeline: Mid-Stage Products (Phase II)
9. Hypercholesterolemia Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.